Prosperodes
Prosperodes is a biomarker strategy company advancing precision medicine for proteopathic neurodegenerations including ALS and FTD. Our SeRAS technology (Seed Replication, Analysis and Subtyping) is aimed to detect and quantify seed biomarkers such as aggregated TDP-43, tau proteins, or alpha-synuclein. It delivers conformation selective and disease-specific insights that can be deployed as translational biomarkers in exploratory research from preclinical discovery to clinical validation. We support biotech and pharma partners with their drug development and actively seek collaborations.
